NCT00317070终止2 期
A Randomized Controlled Trial to Evaluate the Efficacy and Tolerability of Intravesical Cocktail and Comparison With Intravesical Dimethyl Sulfoxide (DMSO) for the Treatment of Painful Bladder Syndrome Including Interstitial Cystitis (PBS/IC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- reduction of frequency of micturition
研究概览
简要总结
The primary objective of this study is to evaluate the efficacy and tolerability of the intravesical cocktail and its comparison with intravesical DMSO in a controlled trial for the treatment of painful bladder syndrome including interstitial cystitis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants should be of age eighteen years or older
- •Participant has painful bladder syndrome and a score of 8 or greater on the painful bladder syndrome symptom index (O'Leary-Sant)
- •Participant should have frequency and urgency of micturition and bladder pain for at least 6 months
- •Participant should have voids at least 8 times during a 24 hour period and at least once during the night as documented in the voiding diary and questionnaire.
- •Urine culture should not show any evidence of urinary tract infection.
- •Participant should be able to understand, speak, and read English.
- •Participant should be willing to take part in the study, including signing this form after carefully reading it.
- •Participant consents to use a medically acceptable method of birth control throughout the entire study period and for four weeks after the study is completed. Medically acceptable methods of contraception that may be used by the study participants and/or their partners include abstinence, birth control pills or patches, diaphragm with spermicide, intrauterine device (IUD), condom and vaginal spermicide, surgical sterilization, vasectomy, or progestin implants or injections.
- •Failure of other treatments for PBS/IC like pentosan polysulfate (failure is defined as a score of +1 [slightly improved] or less on a global assessment response [GRA] 23 question to previous therapy)
排除标准
- •Participants who have undergone cystoscopy within 4 weeks of screening visit
- •Participants had other treatment given into the bladder in the past 4 weeks
- •Participants have used a new drug in the past 4 weeks which could affect bladder symptoms (some antidepressants, anticholinergics, antihistamines)
- •Past history of treatment with cyclophosphamide
- •A positive pregnancy test at the time of screening
- •Currently breast feeding
- •History of uterine, cervical, or vaginal cancer during the past 3 years
- •History of significant vaginitis
- •History of major surgery in the last 6 months
- •Positive tests for HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV)
- •History of immune deficiency diseases
- •History of bleeding disorders
- •History of serious social, mental, or medical conditions that would stop patient from taking part in the study
- •History of alcohol or drug abuse within the last 5 years
- •Participants who have history of prostate cancer or are being treated for chronic bacterial prostatitis
- •History of liver disease or significant medical problem which the investigator considers a risk for patient to be a part of the study
- •History of any of the following: neurogenic bladder radiation to pelvic area, inflammation of the bladder wall because of tuberculosis, schistosomiasis, bladder or ureteric calculi, or active genital herpes within 3 months of screening
- •Known hypersensitivity to one of the agents used in the intravesical instillation
- •Use of any investigational drug or device in the last 6 months
- •Participants who are unwilling or unable to abide by the requirements of the study
研究组 & 干预措施
DMSO
Active Comparator
Intravesical installation
干预措施: dimethyl sulfoxide (Drug)
Cocktail
Experimental
干预措施: IC Cocktail (Drug)
结局指标
主要结局
reduction of frequency of micturition
时间窗: 16 weeks
次要结局
- reduction in pain(16 weeks)
- overall improvement of symptoms(16 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Reperfusion With Hypothermia in Acute Ischemic StrokeIschemic StrokeRevascularizationEndovascular TreatmentReperfusion InjuryNCT05676957Liping Liu30
已完成
3 期
Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)Age-Related Macular DegenerationNCT03668054Laboratorio Elea Phoenix S.A.22
已完成
2 期
Study Evaluating Vabicaserin in Subjects With SchizophreniaSchizophreniaNCT00563706Pfizer199
进行中（未招募）
1 期
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's DiseaseAlzheimer's DiseaseNCT02899091CHABiotech CO., Ltd24
已完成
1 期
Safety and Pharmacokinetic Study of EO9(Intravesical Instillation)Bladder CancerNCT01373398Handok Inc.11